2 April 2014
Details
Amyris
announced that it is entering into
a collaborative research and development agreement
with BASF SE(XETRA:BAS).
Under the agreement,
Amyris will use its strain engineering technology to
develop a microorganism capable of
producing a target molecule identified by BASF.
John Melo, President & CEO of Amyris.
Amyris will seek to develop strains capable of
producing a relevant target molecule for BASF,
which could help performance and competitiveness
with the traditional sources for that molecule.
Amyris's technology platform and
BASF's capabilities and superior market leadership
in the chemicals industry are complementary,
and, I believe, our two companies can build on
this initial effort to lead the way to
innovative renewable chemicals produced
through industrial biotechnology,"
Based on success of the initial development program,
the companies expect to collaborate further
on a strain development program and
consider other joint research and
development opportunities.
WWW.CHEMWINFO.COM BY KHUN PHICHAI
